+
 
For the best experience, open
m.thewire.in
on your mobile browser or Download our App.
You are reading an older article which was published on
Jun 30, 2020

Watch | COVID-19 Bulletin: India's First Vaccine Candidate Gets Regulatory Nod for Human Trials

Hyderabad-based vaccine manufacturer, Bharat Biotech, has been accorded permission by the Drug Controller General of India (DCGI) to initiate Phase I & II human clinical trials.

According to media reports, the Hyderabad-based vaccine manufacturer, Bharat Biotech, has been accorded permission by the Drug Controller General of India (DCGI) to initiate Phase I & II human clinical trials for India’s first vaccine candidate against COVID-19.

The vaccine has been named Covaxin and is an inactivated vaccine developed indigenously. It was developed after the National Institute of Virology, Pune isolated a strain of the SARS-CoV-2 and transferred it to the company. Human clinical trials are scheduled to start across India in July 2020.

Make a contribution to Independent Journalism
facebook twitter